CRIS
Curis, Inc.
There isn't enough reported data to score CRIS yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CRIS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
CRIS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRIS PE Valuation
CRIS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CRIS Forward outlook
There aren't enough analyst estimates for CRIS to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CRIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.02 | +$92.58 |
| Q1 2026 | -$11.60 | +$110.00 |
| Q4 2025 | -$11.60 | +$126.00 |
| Q3 2025 | -$70.40 | +$85.80 |
| Q2 2025 | -$94.60 | +$70.20 |
| Q1 2025 | -$121.60 | +$50.60 |
| Q4 2024 | -$137.60 | +$41.60 |
| Q3 2024 | -$156.20 | +$30.40 |
CRIS is still losing money, but far less than before: $2.02 per share over the past year, against $388.00 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CRIS on earnings quality, reporting a profit while its opponent remains loss making.
CRIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1.1M | -66% |
| Q3 2025 | $3.2M | +8.4% |
| Q2 2025 | $2.7M | +8% |
| Q1 2025 | $2.4M | +14% |
| Q4 2024 | $3.3M | +24% |
| Q3 2024 | $2.9M | +3.5% |
| Q2 2024 | $2.5M | +16% |
| Q1 2024 | $2.1M | -9.2% |
CRIS's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1724% | +1993 points |
| Q3 2025 | -218% | +143 points |
| Q2 2025 | -300% | +191 points |
| Q1 2025 | -427% | +171 points |
| Q4 2024 | -269% | +184 points |
| Q3 2024 | -361% | +76 points |
| Q2 2024 | -491% | +61 points |
| Q1 2024 | -598% | -92 points |
CRIS's operating margin was 1724% last quarter, up 1993 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CRIS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
CRIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.6M | -$1.6M |
| Q1 2026 | -$9M | -$1.7M |
| Q4 2025 | -$6.4M | +$2.9M |
| Q3 2025 | -$5.6M | +$367K |
| Q2 2025 | -$8M | +$3.1M |
| Q1 2025 | -$7.3M | +$6M |
| Q4 2024 | -$9.3M | +$926K |
| Q3 2024 | -$5.9M | +$2.2M |
CRIS has burned cash in almost every quarter: −$31M over the past year, against −$30M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CRIS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +121% | +1.2M shares |
| 1 year | +238% | +1.5M shares |
| 3 years | +784% | +1.9M shares |
| 5 years | +1187% | +2M shares |
| Available history | +2473% | +2.1M shares |
CRIS has 2M diluted shares, up 238% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CRIS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRIS Net Leverage
CRIS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CRIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 7.6 | Oversold |
CRIS's weekly RSI is 24 (oversold) and its Stochastic is 8 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRIS PE vs Healthcare Sector
CRIS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 12% below |
| 20 week MA | $2.20 | 74% below |
| 50 week MA | $10.3 | 94% below |
| 100 week MA | $26.8 | 98% below |
| 200 week MA | $118.4 | 100% below |
CRIS is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CRIS on trend strength, trading above more of its moving averages.
CRIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $620.0 | $3,180.0 | +413% |
| 2021 | $3,180.0 | $2,072.0 | -35% |
| 2022 | $2,072.0 | $197.4 | -90% |
| 2023 | $197.4 | $255.0 | +29% |
| 2024 | $255.0 | $65.0 | -75% |
| 2025 | $65.0 | $21.2 | -67% |
| 2026 YTD | $21.2 | $0.57 | -97% |
CRIS's yearly returns have swung widely, from +413% in 2020 to −90% in 2022. It's down 97% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CRIS on returns for 2026, with the stronger performance.